Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU

Journal of Pharmacy and Pharmacology

Volumn 59, Issue 1, 2007, Pages 105-114

  Murphy, Susan ^a   Boyle, Frances M ^a   Davey, Ross A ^a   Gu, Xiao Qing ^a   Mather, Laurence E ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; CYTOTOXIC AGENT; THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHIRALITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG POTENTIATION; DRUG RESPONSE; DRUG TISSUE LEVEL; ENANTIOMER; ENANTIOSELECTIVITY; FEMALE; GLIOSARCOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MONOTHERAPY; NONHUMAN; RAT; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CISPLATIN; DISEASE MODELS, ANIMAL; FEMALE; GLIOMA; IMMUNOSUPPRESSIVE AGENTS; NEOPLASM TRANSPLANTATION; RATS; RATS, INBRED F344; STEREOISOMERISM; THALIDOMIDE; TISSUE DISTRIBUTION;

EID: 33846367764     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.59.1.0014     Document Type: Article

References (18)

1. Barker, M., Hoshino, T., Gurcay, O., Wilson, C. B., Nielsen, S. L., Downie, R. (1973) Development of an animal brain tumor model and its response to therapy with 1,3-bis(2-chloroethyl)-1-nitroso-urea. Cancer Res. 33: 976-986
2. Chung, F., Lu, J., Palmer, B. D., Kestell, P., Browett, P., Baguley, B. C., Tingle, M., Ching, L. M. (2004) Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. Clin. Cancer Res. 10: 5949-5956
3. Ding, Q., Kestell, P., Baguley, B. C., Palmer, B. D., Paxton, J. W., Muller, G., Ching, L. M. (2002) Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide. Cancer Chemother. Pharmacol. 50: 186-192
4. Eriksson, T., Björkman, S., Roth, B., Höglund, P. (2000) Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. J. Pharm. Pharmacol. 52: 807-817
5. Eriksson, T., Björkman, S., Höglund, P. (2001) Clinical pharmacology of thalidomide. Eur. J. Clin. Pharmacol. 57: 365-376
6. Huang, Y. J., Liao, J. F., Tsai, T. H. (2005) Concurrent determination of thalidomide in rat blood, brain and bile using multiple microdialysis coupled to liquid chromatography. Biomed. Chromatogr. 19: 488-493
7. Khor, S. P., Mayersohn, M. (1991) Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. I. Theoretical considerations. Drug Metab. Dispos. 19: 478-485
8. Khor S. P., Bozigian, H., Mayersohn, M. (1991) Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. II. Distribution of phencyclidine in the rat. Drug Metab. Dispos. 19: 486-490
9. Kimler, B. F. (1994) The 9L rat brain tumor model for pre-clinical investigation of radiation-chemotherapy interactions. J. Neuro-Oncol. 20: 103-109
10. Matthews, S. J., McCoy, C. (2003) Thalidomide: a review of approved and investigational uses. Clin. Ther. 25: 342-395
11. Murphy-Poulton, S. F., Boyle, F., Gu, X.-Q., Mather, L. E. (2006) Thalidomide enantiomers: determination in biological samples by HPLC and vancomycin-CSP. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 831: 48-56
12. Schumacher, H., Blake, D. A., Gillette, J. R. (1968) Disposition of thalidomide in rabbits and rats. J. Pharmacol. Exp. Ther. 160: 201-211
13. Schumacher, H. J., Wilson, J. G., Terapane, J. F., Rosedale, S. L. (1970) Thalidomide: disposition in rhesus monkey and studies of its hydrolysis in tissues of this and other species. J. Pharmacol. Exp. Ther. 173: 265-269
14. Sleijfer, S., Kruit, W. H., Stoter, G. (2004) Thalidomide in solid tumours: the resurrection of an old drug. Eur. J. Cancer 40: 2377-2382
15. Teo, S. K., Colburn, W. A., Tracewell, W. G., Kook, K. A., Stirling, D. I., Jaworsky, M. S., Scheffler, M. A., Thomas, S. D., Laskin, O. L. (2004) Clinical pharmacokinetics of thalidomide. Clin. Pharmacokinet. 43: 311-327
16. Yang, X., Hu, Z., Chan, S. Y., Ho, P. C., Chan, E., Duan, W., Goh, B. C., Zhou, S. (2005) Determination of thalidomide by high performance liquid chromatography: plasma pharmacokinetic studies in the rat. J. Pharm. Biomed. Anal. 39: 299-304
17. Zhou, S., Li, Y., Kestell, P., Schafer, P., Chan, E., Paxton, J.W. (2005) Transport of thalidomide by the human intestinal caco-2 monolayers. Eur. J. Drug. Metab. Pharmacokinet. 30: 49-61
18. Zimmermann, C., Gutmann, H., Drewe, J. (2006) Thalidomide does not interact with P-glycoprotein. Cancer Chemother. Pharmacol. 57: 599-606